DOCSLIB.ORG

APPENDIX a Scoping Letter, NOP, and NOP Comments

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
APPENDIX a Scoping Letter, NOP, and NOP Comments APPENDIX A Scoping Letter, NOP, and NOP Comments THE CITY OF SAN DIEGO PLANNING DEPARTMENT Date of Notice: November 24, 2014 PUBLIC NOTICE OF THE PREPARATION OF A PROGRAM ENVIRONMENTAL IMPACT REPORT AND A SCOPING MEETING INTERNAL ORDER No. 21003411 PUBLIC NOTICE: The City of San Diego as the Lead Agency has determined that the project described below will require the preparation of a Program Environmental Impact Report (PEIR) in compliance with the California Environmental Quality Act (CEQA). This Notice of Preparation of a PEIR and Scoping Meeting was publicly noticed and distributed on November 24, 2014. This notice was published in the SAN DIEGO DAILY TRANSCRIPT and placed on the City of San Diego website at: http://www.sandiego.gov/city-clerk/officialdocs/notices/index.shtml SCOPING MEETING: Two public scoping meetings will be held by the City of San Diego's Planning Department one on Tuesday, December 9, 2014 from 5:30 p.m. to 7:30 PM at the South Bay Recreation Center located at 1885 Coronado Avenue, San Diego CA 92154, and one on Thursday, December 11, 2014 from 6:00 PM to 8:00 PM at the Public Utilities Department Metropolitan Operations Complex located at 9192 Topaz Way, San Diego CA 92123. Please note that depending on the number of attendees, the meeting could end earlier than the end times noted above. Verbal and written comments regarding the scope and alternatives of the proposed EIR will be accepted at the meeting. Please send in written/mail-in comments may also be sent to the following address: Myra Herrmann, Environmental Planner, City of San Diego Development Services Center, 1222 First Avenue, MS 501, San Diego, CA 92101 or e-mail your comments to [email protected] with the Project Name and Number in the subject line Number in the subject line within 30 days of the receipt of this notice/date of the Public Notice above. Responsible agencies are requested to indicate their statutory responsibilities in connection with this project when responding. An EIR incorporating public input will then be prepared and distributed for the public to review and comment. PROJECT NAME I No.: PURE WATER PROGRAM I 386038 COMMUNITY AREAS: Citywide COUNCIL DISTRICT: All Council Districts PROJECT DESCRIPTION: The Pure Water San Diego Program (Pure Water Program) is the City of San Diego Public Utilities Department (PUD) proposed program to provide a safe, secure, and sustainable local drinking water supply for San Diego. Advanced water purification technology will be used to produce potable water from recycled water. The Pure Water Program consists of the design and construction of new advanced water treatment facilities, wastewater treatment facilities, pump stations, transmission lines, and pipelines. The City of San Diego (City) and its regional partners face signiticant issues with water supply and wastewater treatment. Water is critical to the health, safety, and quality oflife of people living in the San Diego region. Currently eight-five percent (85%) of the region's water supply is imported. The region's reliance on imported water causes our water supply to be vulnerable to impacts from shortages and susceptible to price increases beyond our control. As sources oflocal water supply are few, we have explored non potable and potable reuse options of treated water. Water reuse is proven, safe, reliable, and is currently in use in other communities in the United States and around the world. A decision must be made regarding the future treatment process at the City of San Diego's Point Loma Wastewater Treatment Plant (PLWTP). The PLWTP operates with a Clean Water Act (CWA) Section 301(h) modified National Pollutant Elimination Discharge System (NPDES) permit which allows the City to operate without full secondary treatment. The current modified permit expires on July 30, 2015. PUD is in the process of submitting a new permit application and working with the Environmental Protection Agency (EPA) as well as with local environmental groups to gain legislative or administrative approval for the concept of "secondary equivalency" within the Clean Water Act -- a plan to meet modified treatment standards that would be the same as if the existing 240 million gallon per day (mdg) PL WTP were converted to secondary treatment standards. The Pure Water Program is a significant water and wastewater Capital Improvement Program that will create up to 83 million gallons per day oflocally controlled water and reduce flows to the PLWTP which would reduce total suspended solids discharged and recycle a valuable and limited resource that is currently discharged to the ocean. The Pure Water Program is a twenty year program that will involve the planning, design, and construction of new advanced water treatment facilities, wastewater treatment facilities, pump stations, and pipelines. The Pure Water program will also include property and easement acquisition, discretionary permitting, property acquisition, financing, facility startup, testing, operation and maintenance of new facilities, and significant public education and community engagement. Applicant: City of San Diego, Public Utilities Department Recommended Finding: Pursuant to Section 15060(d) of the CEQA Guidelines, it appears that the proposed project may result in significant environmental impacts in the following areas: Land Use, Visual Effects and Neighborhood Character, Air Quality/Odor, Greenhouse Gas Emissions, Biological Resources, Historical Resources, Health and Safety, Hydrology and Water Quality, Geology/Soils and Seismic Hazards, Noise Paleontological Resources, Transportation/Circulation, Energy, Public Services and Facilities, Public Utilities, and Water Supply. Availability in Alternative Format: To request the this Notice or the City's letter to the applicant detailing the required scope of work (EIR Scoping Letter) in alternative format, call the Planning Department at (619) 235-5200 (800) 735-2929 (TEXT TELEPHONE). Additional Information: For environmental review infonnation, contact Myra Hemnann at (619) 446-5372. The Scoping Letter and supporting documents may be reviewed, or purchased for the cost of reproduction, in the Planning Department on the at the Fifth floor of the Development Services Center. For information regarding public meetings/hearings on this project, contact the Project Manager, Keli Balo, at (858) 292-6423 or via email: [email protected]. This notice was published in the SAN DIEGO DAILY TRANSCRIPT and distributed on November 24, 2014. Cathy Winterrowd Deputy Director Planning Department DISTRIBUTION: See Attached ATTACHMENTS: Figure 1 - Project Components and Location Map DISTRIBUTION: United States Government Federal Aviation Administration (1) Naval Facilities Engineering Command, SW Division, Environmental Planning (12) MCAS Miramar (13) Marine Corps Recruit Depot Facilities Div. (14) Environmental Protection Agency (19) U. S. Fish and Wildlife Service (23) USDA Natural Resources Conservation Services (25) Army Corps of Engineers (26) Cleveland National Forest (29) State of California Cal trans District 11 (31) Department of Fish and Wildlife (32) Cal Recycle (35) Dept of Health Services Division of Drinking Water & Environmental Mgmt (36) California Environmental Protection Agency (3 7A) Department of Toxic Substance Control (39) State Parks (40A) Department of Parks and Recreation (40B) Natural Resources Agency (43) Regional Water Quality Control Board, Region 9 (44) Department of Water Resources (45) State Clearinghouse ( 46A) California Coastal Commission (4 7) California Air Resources Board (49) California Transportation Commission ( 51) California Transportation Commission (51A) California Boating & Waterways (52) California State Coastal Conservancy (54) State Water Resources Control Board Division of Clean Water Programs (55) Native American Heritage Commission (56) California Energy Commission (59) California Dept. of Conservation ( 60) California State Lands Commission (62) San Diego County Agriculture Department (64) Air Pollution Control Board ( 65) Planning and Land Use ( 68) Parks Department ( 69) Noise Control Hearing Board (71) Public Works (72) County Water Authority (73) Department of Enviromnental Health (76) Pure Water Program 1 City of San Diego Office of the Mayor (91) Scott Chadwick Stacey LoMedico Tony Heinrichs David Graham Ron Villa Council President Gloria, District 3 Council President Pro Tern Lightner, District 1 Councilmember Harris, District 2 Councilmember Cole, District 4 Councilmember Kersey, District 5 Councilmember Zapf, District 6 Councilmember Sherman, District 7 Councilmember Alvarez, District 8 Councilmember Emerald, District 9 Public Utilities Department (Applicant) Halla Razak, Director Mike Elling Keli Balo Planning Department Tom Tomlinson, Interim Director Cathy Winterrowd Nancy Bragado Myra Herrmann Kristy Forburger Jeanne Krosch Development Services Department Robert Vacchi, Director Kerry Santoro Martha Blake Jeff Szymanski Elizabeth Shearer-Nguyen Anna McPherson Anita Eng Leonard Wilson Public Works Department James Nagelvoort, Director Marnell Gibson Carrie Purcell Economic Development Russ Gibbon (MS 56D) Jim Davies (MS 56D) Park and Recreation Department Herman Parker, Director Chris Zirkle Pure Water Program 2 Fire-Rescue Department Chief Javier Mainar Fire and Life Safety Services (79) Kenneth Barnes, Fire -Rescue Dept Logistics (80) Police Department Chief Shelley Zimmerman Environmental Services Department Mario Sierra, Director Darren Greenhalgh Lisa Wood Transportation & Storm
Load more

Recommended publications
  • Triptans Step Therapy/Quantity Limit Criteria
    Triptans Step Therapy/Quantity Limit Criteria Program may be implemented with the following options 1) step therapy 2) quantity limits or 3) step therapy with quantity limits For Blue Cross and Blue Shield of Illinois Option 1 (step therapy only) will apply. Brand Generic Dosage Form Amerge® naratriptan tablets Axert® almotriptan tablets Frova® frovatriptan tablets Imitrex® sumatriptan injection*, nasal spray, tablets* Maxalt® rizatriptan tablets Maxalt-MLT® rizatriptan tablets Relpax® eletriptan tablets Treximet™ sumatriptan and naproxen tablets Zomig® zolmitriptan tablets, nasal spray Zomig-ZMT® zolmitriptan tablets * generic available and included as target agent in quantity limit edit FDA APPROVED INDICATIONS1-7 The following information is taken from individual drug prescribing information and is provided here as background information only. Not all FDA-approved indications may be considered medically necessary. All criteria are found in the section “Prior Authorization Criteria for Approval.” Amerge® Tablets1, Axert® Tablets2, Frova® Tablets3,Imitrex® injection4, Imitrex Nasal Spray5, Imitrex Tablets6, Maxalt® Tablets7, Maxalt-MLT® Tablets7, Relpax® Tablets8, Treximet™ Tablets9, Zomig® Tablets10, Zomig-ZMT® Tablets10, and Zomig® Nasal Spray11 Amerge (naratriptan), Axert (almotriptan), Frova (frovatriptan), Imitrex (sumatriptan), Maxalt (rizatriptan), Maxalt-MLT (rizatriptan orally disintegrating), Relpax (eletriptan), Treximet (sumatriptan/naproxen), Zomig (zolmitriptan), and Zomig-ZMT (zolmitriptan orally disintegrating) tablets, and Imitrex (sumatriptan) and Zomig (zolmitriptan) nasal spray are all indicated for the acute treatment of migraine attacks with or without aura in adults. They are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Safety and effectiveness of all of these products have not been established for cluster headache, which is present in an older, predominantly male population.
    [Show full text]
  • Guideline for Preoperative Medication Management
    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
    [Show full text]
  • NEW PATIENT QUESTIONNAIRE - Page 1
    __________________________ Clinical Neurosciences Center NEW PATIENT QUESTIONNAIRE - Page 1 Provider you will be seeing: Date of Appointment: Patient Name: Date of Birth: Age: Home Address / City / State / Zip: Home Phone: Work Phone: Cell: Email: Emergency Contact: Phone: PHYSICIAN INFORMATION - What is the name of your PRIMARY CARE PROVIDER: Address / City / State: Phone: What is the name your REFERRING PROVIDER (if different from above): Address / City / State: Phone: HEADACHE SPECIFIC QUESTIONS - What is your biggest concern about your headaches: Do you have sick / severe headaches: YES NO Date sick / severe headache started: How many sick / severe headaches have you had in your life: 0-2 3-10 11-20 21-50 51-100 >100 Frequency of sick / severe headaches (per month and per year): AGE MONTH YEAR DESCRIBE As a child less than 12 years As an adolescent 13-18 years As a young adult 19-30 years As an adult over 30 years Were you adopted: YES NO Does anyone in the family have headaches (migraine, sick, sinus, tension, cluster, other): RELATION YES NO DESCRIBE RELATION YES NO DESCRIBE Mother Father M. Gma P. Gma M. Gpa P. Gpa M. Aunts P. Aunts M. Uncles P. Uncles Sisters Brothers Daughters Sons Were you ever carsick as a child: YES NO NEW PATIENT QUESTIONNAIRE - Page 2 SOME PEOPLE HAVE MORE THAN ONE TYPE OF HEADACHE - How many days have you had a headache in the last: month: days 3 months: days 6 months: days Visits to the ER in the last 12 months: visits Days missed at work or school in the last month: days On a scale of 1-10, on average,
    [Show full text]
  • NARATRIPTAN 2.5 MG FILM-COATED TABLETS [Naratriptan (As Naratriptan Hydrochloride)] Read All of This Leaflet Carefully Before You Start Taking This Medicine
    PACKAGE LEAFLET: INFORMATION FOR THE USER NARATRIPTAN 2.5 MG FILM-COATED TABLETS [Naratriptan (as naratriptan hydrochloride)] Read all of this leaflet carefully before you start taking this medicine. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist (chemist). • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their CODE symptoms are the same as yours. CODE • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. In this leaflet: 1. What Naratriptan is and what it is used for 2. Before you take Naratriptan 3. How to take Naratriptan 4. Possible side effects 5. How to store Naratriptan 6. Further information Zentiva 1. What Naratriptan is and what it is used for Brand: PIL NARATRIPTAN 2.5MG 6 AND 12 FCT 156X348MM Naratriptan contains naratriptan (hydrochloride), which belongs to a group of medicines called triptans (also Category: LEAFLET known as 5-HT1 receptor agonists). Argus Code: 000 Naratriptan tablets are used to treat migraine with or without aura. Spec No: 00000 Migraine symptoms may be caused by the temporary widening of blood vessels in the head. Naratriptan tablets Supersedes: 00000 are believed to reduce the widening of these blood vessels. This in turn helps to take away the headache and Core Spec No: 00000 relieve other symptoms of a migraine attack, such as feeling or being sick (nausea or vomiting) and sensitivity to light and sound.
    [Show full text]
  • Triptan Therapy for Acute Migraine
    Triptan Therapy for Acute Migraine Headache John Farr Rothrock, MD University of Alabama at Birmingham, Birmingham, AL Deborah I. Friedman, MD, MPH University of Texas Southwestern, Dallas, TX The “triptans” are 5HT-1B/1D receptor agonists that were developed to treat acute migraine and acute cluster headache. Sumatriptan, the original triptan preparation, has been in general use since 1993, so there has been considerable experience with triptans over time. There are currently seven oral triptans on the market in the United States: sumatriptan (Imitrex™), naratriptan (Amerge™), zolmitriptan (Zomig™), rizatriptan (Maxalt™), almotriptan (Axert™), frovatriptan (Frova™), and eletriptan (Relpax™); brand names may differ by country. There is also a combination preparation of oral sumatriptan/naproxen (Treximet™). Two triptans (sumatriptan, zolmitriptan) are marketed as nasal sprays, and sumatriptan is available for subcutaneous injection, including a needle-free subcutaneous delivery system (Sumavel™). Sumatriptan suppositories are marketed in Europe but not in North America. Zolmitriptan and rizatriptan are sold in an oral disintegrating tablet or “melt” formulation as well as in tablet form; while the “melt” formulations may be more convenient (no liquid is required to propel them into the stomach), they are absorbed similarly to regular tablets and there is no evidence to suggest that they work faster than the tablet formulations. Some patients with migraine-associated nausea prefer the disintegrating tablets while others cannot tolerate their taste. Although all of the triptans initially were investigated for the treatment of migraine headache of moderate to severe intensity and were superior to placebo in those pivotal trials, they appear to be more consistently effective when used to treat migraine earlier in the attack, when the headache is still mild to moderate.
    [Show full text]
  • Triptans: Almotriptan, Amerge®, Axert®, Frova®, Imitrex® and Sumatriptan Tablets/Nasal Spray/Injection, Maxalt/MLT®, Naratriptan, Onzetra™
    Drug Therapy Guidelines Triptans: almotriptan, Amerge®, Axert®, Frova®, Imitrex® and sumatriptan tablets/nasal spray/injection, Maxalt/MLT®, naratriptan, Onzetra™ Xsail™, Relpax® and eletriptan tablets, rizatriptan/ODT, Sumavel®, Tosymra™, Treximet®, Zembrace™ SymTouch™, zolmitriptan/ODT tablets, Applicable Zomig/ZMT® tablets/nasal spray Medical Benefit Effective: 5/28/2021 Pharmacy- Formulary 1 x Next Review: 3/22 Pharmacy- Formulary 2 x Date of Origin: 8/29/06 Pharmacy- Formulary 3/Exclusive x Review Dates: 8/06, 11/07, 12/08, 12/09, 6/10, 3/11, 3/12, 3/13, Pharmacy- Formulary 4/AON x 3/14, 3/15, 3/16, 3/17, 3/18, 3/19, 3/20, 2/21, 3/21 I. Medication Description Serotonin receptor agonists are used to treat (not prevent) acute attacks of migraine headaches. These medications work by binding to specific serotonin receptors in the brain which in turn decreases the release of chemicals responsible for the vasodilation of cerebral blood vessels, decreases the activity of pain signaling neurons, and reduces inflammation. II. Position Statement For all lines of business, coverage is provided immediately, without requiring prior authorization, for preferred/formulary medications with associated quantity limit restrictions. Quantity limitations criteria do not apply when the medication is requested by a neurologist. Coverage is determined through a prior authorization process with supporting clinical evidence for all other requests for members aged 18 and older. III. Policy Formulary 1: See Sections B and C Formulary 2: See Sections A and C Formulary 3/Exclusive: See Sections A and C Formulary 4/AON: See Sections A and C A. Non-preferred medications: Amerge, Axert, Frova, Imitrex, Maxalt, Onzetra, Relpax, Tosymra, Treximet, Zembrace, Zomig, Zolmitriptan nasal spray Plan-preferred medications: eletriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan tablets, zolmitriptan oral disintegrating tablets B.
    [Show full text]
  • Design, Synthesis and Biological Activity of Novel Dimethyl-{2-[6-Substituted-Indol-1-Yl]-Ethyl}-Amine As Potent, Selective, and Orally-Bioavailable 5-HT1D Agonists
    Bioorganic & Medicinal Chemistry Letters 13 (2003) 4409–4413 Design, Synthesis and Biological Activity of Novel Dimethyl-{2-[6-substituted-indol-1-yl]-ethyl}-amine as Potent, Selective, and Orally-Bioavailable 5-HT1D Agonists Methvin Isaac,a,* Malik Slassi,a Tao Xin,a Jalaj Arora,a Anne O’Brien,a Louise Edwards,a Neil MacLean,a Julie Wilson,a Lidia Demschyshyn,a Phillipe Labrie,a Angela Naismith,a Shawn Maddaford,a Damon Papac,b Shuree Harrison,b Hua Wang,b Stan Draperb and Ashok Tehima aNPS Pharmaceuticals Inc., 6850 Goreway Drive, Mississauga, ON, Canada L4V 1V7 bNPS Pharmaceuticals Inc., 420 Chipeta Way, Salt Lake City, UT 84108, USA Received 25 April 2003; accepted 12 September 2003 Abstract—A novel series of highly potent human 5-HT1D agonists, dimethyl-{2-[6-substituted-indol-1-yl]-ethyl}-amine, was syn- thesized. Structure–activity relationship (SAR) investigation revealed 4-[1-(2-dimethylamino-ethyl)-1H-indol-6-yl]-tetrahydro-thio- pyran-4-ol, 11b (ALX-2732), as a potent (Ki=2.4 nM) agonist at the human 5-HT1D receptor with good selectivity over the other serotonin receptor subtypes. This compound demonstrated favorable in vitro metabolic stability in human and rat liver microsomes and was found to be orally bioavailable in rats (Fpo=51%). # 2003 Elsevier Ltd. All rights reserved. The 5-HT1D receptor functions as a terminal autoreceptor trigeminal ganglia, mRNA’s encoding for both h5- regulating the synthesis and release of 5-hydroxy- HT1D and h5-HT1B receptor subtypes (previously tryptamine from serotonergic neurons, and it also acts as termed 5-HT1Da and 5-HT1Db, respectively) appear to a presynaptic heteroreceptor regulating the release of be present.
    [Show full text]
  • Eletriptan in the Management of Acute Migraine
    TAN0010.1177/1756285616650619Therapeutic Advances in Neurological DisordersM Capi, M Curto View metadata, citation and similar650619research-article2016 papers at core.ac.uk brought to you by CORE provided by Archivio della ricerca- Università di Roma La Sapienza Therapeutic Advances in Neurological Disorders Review Ther Adv Neurol Disord Eletriptan in the management of acute 2016, Vol. 9(5) 414 –423 DOI: 10.1177/ migraine: an update on the evidence for 1756285616650619 © The Author(s), 2016. Reprints and permissions: efficacy, safety, and consistent response http://www.sagepub.co.uk/ journalsPermissions.nav Matilde Capi, Martina Curto, Luana Lionetto, Fernando de Andrés, Giovanna Gentile, Andrea Negro and Paolo Martelletti Abstract: Migraine is a multifactorial, neurological and disabling disorder, also characterized by several autonomic symptoms. Triptans, selective serotonin 5-HT1B/1D agonists, are the first-line treatment option for moderate-to-severe headache attacks. In this paper, we review the recent data on eletriptan clinical efficacy, safety, and tolerability, and potential clinically relevant interactions with other drugs. Among triptans, eletriptan shows a consistent and significant clinical efficacy and a good tolerability profile in the treatment of migraine, Correspondence to: especially for patients with cardiovascular risk factors without coronary artery disease. It Martina Curto, MD Sapienza University shows the most favorable clinical response, together with sumatriptan injections, zolmitriptan of Rome, Azienda and rizatriptan. Additionally, eletriptan shows the most complex pharmacokinetic/dynamic Ospedaliera Sant’Andrea Via di Grottarossa 1035- profile compared with the other triptans. It is metabolized primarily by the CYP3A4 hepatic 1039, Rome 00189, Italy enzyme and therefore the concomitant administration of CYP3A4-potent inhibitors should [email protected] Matilde Capi, MSc be carefully evaluated.
    [Show full text]
  • Comparison of Sumatriptan and Naratriptan Using a Markov Model Approach
    Comparison of sumatriptan and naratriptan using a Markov model approach Hugo Maasa, Meindert Danhofa and Oscar Della Pasquaa,b aLACDR, Division of Pharmacology, Leiden University, P.O. Box 9502, 2300 RA Leiden, The Netherlands bGlaxoSmithKline, Clinical Pharmacology & Discovery Medicine, Greenford Road, Greenford UB6 0HE, United Kingdom Introduction A hidden Markov model has been developed to predict the effects of triptans on anti- Sumatriptan and naratriptan are 5HT1B/D receptor agonists commonly prescribed for migraine headache. Their mechanism of action involves 5HT1B receptor-mediated migraine treatment (Figure 2). The model comprises three states, the transitions between constriction of intracranial blood vessels and 5HT1D receptor-mediated inhibition of pain which are based on the clinical differentiation between attaining pain relief (from a signal transmission to central trigeminal neurons. It was recently suggested that the headache score 3 or 2 to 1 or 0) and attaining pain resolution (from a headache score 3 or effectiveness of triptans can be limited after sensitisation of central trigeminal neurons 2 to 0). As shown in Figure 1, trigeminal pathophysiology may well be a biological substrate (Figure 1). The assessment of treatment response in migraine ought therefore to consider for this differentiation. The hidden Markov model was applied to predict the concentration- drug access to target sites and timing of administration. effect relationship for sumatriptan and naratriptan. A major advantage of this approach is Sumatriptan and naratriptan distinctly differ in their pharmacokinetic properties. the the ability to estimate transition rates from one state to another, which makes the Sumatriptan has a lower elimination half-life than naratriptan and is less lipophilic.
    [Show full text]
  • Thursday April 29, 1999
    4±29±99 Vol. 64 No. 82 Thursday Pages 23007±23164 April 29, 1999 Briefings on how to use the Federal Register For information on briefings in Washington, DC, see announcement on the inside cover of this issue. federal register 1 VerDate 26-APR-99 16:58 Apr 28, 1999 Jkt 183247 PO 00000 Frm 00001 Fmt 4710 Sfmt 4710 E:\FR\FM\29APWS.XXX pfrm01 PsN: 29APWS II Federal Register / Vol. 64, No. 82 / Thursday, April 29, 1999 The FEDERAL REGISTER is published daily, Monday through SUBSCRIPTIONS AND COPIES Friday, except official holidays, by the Office of the Federal Register, National Archives and Records Administration, PUBLIC Washington, DC 20408, under the Federal Register Act (44 U.S.C. Subscriptions: Ch. 15) and the regulations of the Administrative Committee of Paper or fiche 202±512±1800 the Federal Register (1 CFR Ch. I). The Superintendent of Assistance with public subscriptions 512±1806 Documents, U.S. Government Printing Office, Washington, DC 20402 is the exclusive distributor of the official edition. General online information 202±512±1530; 1±888±293±6498 Single copies/back copies: The Federal Register provides a uniform system for making available to the public regulations and legal notices issued by Paper or fiche 512±1800 Federal agencies. These include Presidential proclamations and Assistance with public single copies 512±1803 Executive Orders, Federal agency documents having general FEDERAL AGENCIES applicability and legal effect, documents required to be published Subscriptions: by act of Congress, and other Federal agency documents of public Paper or fiche 523±5243 interest. Assistance with Federal agency subscriptions 523±5243 Documents are on file for public inspection in the Office of the Federal Register the day before they are published, unless the issuing agency requests earlier filing.
    [Show full text]
  • (Imigran, Suvalan) and Zolmitriptan 2.5 Mg (Zomig) Tablets for Migraine
    Naratriptan 2.5 mg (Naramig), sumatriptan 50 mg (Imigran, Suvalan) and zolmitriptan 2.5 mg (Zomig) tablets for migraine Summary PBS listing The maximum quantity has been increased from 2 to 4 tablets. The PBS listing for the triptans (naratriptan, sumatripan and zolmitriptan) is otherwise unchanged. Reason for listing The PBAC recommended an increase in the maximum quantity to cater more adequately for patients who have more than one migraine each month. Place in therapy Triptans should be reserved for patients who have had an adequate trial of a prophylactic agent and in whom other agents have failed to relieve previous attacks. Safety issues There has been no change in the safety considerations for triptans. Serious cardiovascular events have been associated with the triptans; it is therefore particularly important to adhere to the dosing recommendations for this class. Ensure that patients are aware of the appropriate dosing of triptans. Dosing issues There has been no change to the dosing recommendations for triptans. PBS listing The maximum quantity has been increased from 2 to 4 tablets.1 The PBS listing for the triptans (naratriptan, sumatriptan and zolmitriptan) is otherwise unchanged: Authority required Migraine attacks in patients receiving, or who have failed a reasonable trial of, prophylactic medication and where attacks in the past have usually failed to respond to oral therapy with ergotamine and other appropriate agents, or in whom these agents are contraindicated. No applications for increased maximum quantities and/or repeats will be authorised. Reason for listing The PBAC recommended an increase in the maximum quantity to cater more adequately for patients who have more than one migraine each month.
    [Show full text]
  • Medication-Guide.Pdf
    Migraine Medication Guide Migraine Medication Guide PREVENTIVE MEDICINES PREVENTIVE MEDICINES Dosing is intended for adults Dosing is intended for adults Migraine Prophylaxis: Level A Pediatric Migraine divalproex/sodium valproate* 500-1000 mg /day Intervention metoprolol 47.5-200 mg/day Analgesics: acetominophen, ibuprofen propranolol* 120-240 mg/day Triptans - FDA approved age 6-17 rizatriptan - weight <40kg (88 lbs), use 5 mg; (candesartan 8-16 mg/day) >40kg (88 lbs) use 10 mg timolol* 10-15 mg/day age 12-17 almotriptan- 6.25-12.5mg PO x1; Max 25/24h; may topiramate* 25-200 mg/day repeat dose x1 after 2h sumatriptan-naproxen sodium 10/60 tab; Max Migraine Prophylaxis: Level B 85/500mg tab per 24h zolmitriptan nasal spray (when nausea or vomiting) - riboavin (vitamin B2) 400 mg/day one 2.5 dose only Off-label use sumatriptan- 25 mg magnesium trimagnesium dicitrate 500-600 mg/day nasal sumatriptan - 5, 10, 25 mg feverfew 50-300 mg q12 zolmitriptan tab and melt tab - 5mg feverfew CO2 extract 2.08-18.75 mg q8 amitriptyline 25-150 mg/day (see below) Menstrual atenolol 100 mg/day (50-200 mg) no FDA approved therapies venlafaxine (ER) -Effexor 150 mg/day (37.5-150 mg) Mild-Moderate symptoms lisinopril 10 mg/day ibuprofen 800 mg every 8-12 hours prn histamine 1-10 mg subc 2x week naproxen 250 mg 1-2 every 8-12 hours prn fenoprofen 200 - 600 mg/day 500 mg every 12 hours prn acetaminophen, aspirin or ibuprofen with or without caffeine ibuprofen 200 mg q12 ketoprofen 50 mg q8 Moderate-Severe symptoms naproxen 500 - 1000 mg/day triptan with or
    [Show full text]